The phase III OAK trial that evaluated safety and efficacy of atezolizumab in patients with NSCLC found a clinically meaningful survival benefit over docetaxel in previously treated patients regardless of PD-L1 expression or histology. The gene discussed is CD274; the disease is non-small cell lung carcinoma.